Cargando…

Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer

Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, seru...

Descripción completa

Detalles Bibliográficos
Autores principales: Pichler, Renate, Gruenbacher, Georg, Culig, Zoran, Brunner, Andrea, Fuchs, Dietmar, Fritz, Josef, Gander, Hubert, Rahm, Andrea, Thurnher, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359386/
https://www.ncbi.nlm.nih.gov/pubmed/28005163
http://dx.doi.org/10.1007/s00262-016-1945-z
_version_ 1782516377827934208
author Pichler, Renate
Gruenbacher, Georg
Culig, Zoran
Brunner, Andrea
Fuchs, Dietmar
Fritz, Josef
Gander, Hubert
Rahm, Andrea
Thurnher, Martin
author_facet Pichler, Renate
Gruenbacher, Georg
Culig, Zoran
Brunner, Andrea
Fuchs, Dietmar
Fritz, Josef
Gander, Hubert
Rahm, Andrea
Thurnher, Martin
author_sort Pichler, Renate
collection PubMed
description Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, serum and urine samples were prospectively collected at baseline, during and after BCG. Th1 (neopterin, tryptophan, kynurenine, kynurenine-to-tryptophan ratio (KTR), IL-12, IFN-γ, soluble TNF-R75 and IL-2Rα) and Th2 (IL-4, IL-10) biomarkers as well as CD4 expression in T helper (Th), effector and regulatory T cells were determined. Local immune cell subsets were measured on formalin-fixed, paraffin-embedded cancer tissue by immunohistochemistry to examine expression of transcription factors that control Th1 (T-bet) and Th2-type (GATA3) immunity. We confirmed a Th2 predisposition with a mean GATA3/T-bet ratio of 5.51. BCG responders showed significantly higher levels of urinary (p = 0.003) and serum neopterin (p = 0.012), kynurenine (p = 0.015), KTR (p = 0.005), IFN-γ (p = 0.005) and IL-12 (p = 0.003) during therapy, whereas levels of IL-10 decreased significantly (p < 0.001) compared to non-responders. GATA3/T-bet ratio correlated positively with serum neopterin (p = 0.008), IFN-γ (p = 0.013) and KTR (p = 0.018) after the first BCG instillation. We observed a significant increase in CD4 expression in the Th cell population (p < 0.05), with only a modest tendency toward higher frequency in responders compared to non-responders (p = 0.303). The combined assessment of GATA3/T-bet ratio, neopterin and KTR may be a useful biomarker in predicting BCG response. Th2-promoting factors such as GATA3 may trigger Th1-type immune responses and thus contribute to the BCG success. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00262-016-1945-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5359386
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-53593862017-04-04 Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer Pichler, Renate Gruenbacher, Georg Culig, Zoran Brunner, Andrea Fuchs, Dietmar Fritz, Josef Gander, Hubert Rahm, Andrea Thurnher, Martin Cancer Immunol Immunother Original Article Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, serum and urine samples were prospectively collected at baseline, during and after BCG. Th1 (neopterin, tryptophan, kynurenine, kynurenine-to-tryptophan ratio (KTR), IL-12, IFN-γ, soluble TNF-R75 and IL-2Rα) and Th2 (IL-4, IL-10) biomarkers as well as CD4 expression in T helper (Th), effector and regulatory T cells were determined. Local immune cell subsets were measured on formalin-fixed, paraffin-embedded cancer tissue by immunohistochemistry to examine expression of transcription factors that control Th1 (T-bet) and Th2-type (GATA3) immunity. We confirmed a Th2 predisposition with a mean GATA3/T-bet ratio of 5.51. BCG responders showed significantly higher levels of urinary (p = 0.003) and serum neopterin (p = 0.012), kynurenine (p = 0.015), KTR (p = 0.005), IFN-γ (p = 0.005) and IL-12 (p = 0.003) during therapy, whereas levels of IL-10 decreased significantly (p < 0.001) compared to non-responders. GATA3/T-bet ratio correlated positively with serum neopterin (p = 0.008), IFN-γ (p = 0.013) and KTR (p = 0.018) after the first BCG instillation. We observed a significant increase in CD4 expression in the Th cell population (p < 0.05), with only a modest tendency toward higher frequency in responders compared to non-responders (p = 0.303). The combined assessment of GATA3/T-bet ratio, neopterin and KTR may be a useful biomarker in predicting BCG response. Th2-promoting factors such as GATA3 may trigger Th1-type immune responses and thus contribute to the BCG success. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00262-016-1945-z) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2016-12-22 2017 /pmc/articles/PMC5359386/ /pubmed/28005163 http://dx.doi.org/10.1007/s00262-016-1945-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Pichler, Renate
Gruenbacher, Georg
Culig, Zoran
Brunner, Andrea
Fuchs, Dietmar
Fritz, Josef
Gander, Hubert
Rahm, Andrea
Thurnher, Martin
Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
title Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
title_full Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
title_fullStr Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
title_full_unstemmed Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
title_short Intratumoral Th2 predisposition combines with an increased Th1 functional phenotype in clinical response to intravesical BCG in bladder cancer
title_sort intratumoral th2 predisposition combines with an increased th1 functional phenotype in clinical response to intravesical bcg in bladder cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359386/
https://www.ncbi.nlm.nih.gov/pubmed/28005163
http://dx.doi.org/10.1007/s00262-016-1945-z
work_keys_str_mv AT pichlerrenate intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT gruenbachergeorg intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT culigzoran intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT brunnerandrea intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT fuchsdietmar intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT fritzjosef intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT ganderhubert intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT rahmandrea intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer
AT thurnhermartin intratumoralth2predispositioncombineswithanincreasedth1functionalphenotypeinclinicalresponsetointravesicalbcginbladdercancer